Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Bladder Cancer, July 2023

Free Subscription


Abstracts

Retrieve all available abstracts of the following 298 articles:
HTML format


 

Single Articles

  1. ZHOU R, Zhou J, Muhuitijiang B, Zeng X, et al
    Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
    Aging (Albany NY). 2023;15.
    PubMed    
    Abstract available

  2. BHONGIR AV, Sampath S, Bonthapally RK, Gudivada KK, et al
    Sequential Application and Post-Test Probability for Screening of Bladder Cancer Using Urinary Proteomic Biomarkers: A Review based Probabilistic Analysis.
    Asian Pac J Cancer Prev. 2023;24:2021-2027.
    PubMed    
    Abstract available

  3. OFFICE FE
    Retraction: Long noncoding RNA SNHG1 activates autophagy and promotes cell invasion in bladder cancer.
    Front Oncol. 2023;13:1228367.
    PubMed    
    Abstract available

  4. BOGUMIL D, Cortessis VK, Wilkens LR, Le Marchand L, et al
    Interethnic Differences in Bladder Cancer Incidence and the Association between Type 2 Diabetes and Bladder Cancer in the Multiethnic Cohort Study.
    Cancer Res Commun. 2023;3:755-762.
    PubMed    
    Abstract available

  5. GUAN X, Lu D, Chen Z, Wang Z, et al
    Non-invasive detection of bladder cancer via microfluidic immunoassay of the protein biomarker NMP22.
    Anal Methods. 2023 Jun 28. doi: 10.1039/d3ay00664.
    PubMed    
    Abstract available

  6. NIKULAINEN I, Salminen AP, Seikkula H, Hogerman M, et al
    Nationwide analysis of survival after radical cystectomy for bladder cancer in Finland.
    Acta Oncol. 2023 Jun 28:1-7. doi: 10.1080/0284186X.2023.2228446.
    PubMed    
    Abstract available

  7. MYINT ZW, Chahine Z, Jayswal R, Bachert E, et al
    Association of CD47 Expression with Clinicopathologic Characteristics and Survival Outcomes in Muscle Invasive Bladder Cancer.
    J Pers Med. 2023;13:885.
    PubMed    
    Abstract available

  8. GILYAZOVA I, Enikeeva K, Rafikova G, Kagirova E, et al
    Epigenetic and Immunological Features of Bladder Cancer.
    Int J Mol Sci. 2023;24:9854.
    PubMed    
    Abstract available

  9. JORDAENS S, Oeyen E, Willems H, Ameye F, et al
    Protein Biomarker Discovery Studies on Urinary sEV Fractions Separated with UF-SEC for the First Diagnosis and Detection of Recurrence in Bladder Cancer Patients.
    Biomolecules. 2023;13:932.
    PubMed    
    Abstract available

  10. LUI G, Minnar CM, Soon-Shiong P, Schlom J, et al
    Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies.
    Cells. 2023;12:1611.
    PubMed    
    Abstract available

  11. ABDELAZIZ A, Sultan M, Hammad MA, Martinez JR Jr, et al
    Endophytic upper tract urothelial carcinoma in a solitary kidney treated by cryotherapy: an unorthodox case for successful management.
    BMC Urol. 2023;23:111.
    PubMed    
    Abstract available

  12. LEE YJ, Kang SG, Kim CH
    Over-expression of Long Non-coding RNA Urothelial Cancer-associated 1 as a Predictive Marker for Prostate Cancer.
    In Vivo. 2023;37:1511-1516.
    PubMed    
    Abstract available

  13. WILLIAMS SB, Janes JL, Howard LE, Yang R, et al
    Exposure to Agent Orange and Risk of Bladder Cancer Among US Veterans.
    JAMA Netw Open. 2023;6:e2320593.
    PubMed    
    Abstract available

  14. SHIRONO Y, Bilim V, Anraku T, Kuroki H, et al
    Targeting Pro-Survival Autophagy Enhanced GSK-3beta Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells.
    Curr Oncol. 2023;30:5350-5365.
    PubMed    
    Abstract available

  15. PANUNZIO A, Gozzo A, Mazzucato G, Ornaghi PI, et al
    Impairment in Activities of Daily Living Assessed by the Barthel Index Predicts Adverse Oncological Outcomes After Radical Cystectomy for Bladder Cancer.
    Clin Genitourin Cancer. 2023 Jun 9:S1558-7673(23)00141.
    PubMed    
    Abstract available

  16. SHEN C, Zhang S, Zhang Z, Yang S, et al
    Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Funct Integr Genomics. 2023;23:211.
    PubMed    
    Abstract available

  17. LEVY JJ, Chan N, Marotti JD, Rodrigues NJ, et al
    Examining longitudinal markers of bladder cancer recurrence through a semiautonomous machine learning system for quantifying specimen atypia from urine cytology.
    Cancer Cytopathol. 2023 Jun 26. doi: 10.1002/cncy.22725.
    PubMed    
    Abstract available

  18. A BUENO AP, Clark O, Turnure M, Moreira ES, et al
    Physician reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact((R)) Survey 2020.
    Future Oncol. 2023 Jun 26. doi: 10.2217/fon-2022-1066.
    PubMed    
    Abstract available

  19. CAGLAYAN A, Horsanali MO
    Can Peripheral Blood Systemic Immune Response Parameters Predict Oncological Outcomes in Patients with Non-Muscle-Invasive Bladder Cancer?
    Niger J Clin Pract. 2023;26:591-598.
    PubMed    
    Abstract available

  20. HONG BA, Zhao Q, Ji YP, Cao YD, et al
    [The preliminary efficacy of "quadri-combination" therapy on the treatment of bladder cancer].
    Zhonghua Yi Xue Za Zhi. 2023;103:1855-1859.
    PubMed    
    Abstract available

  21. CAYUELA L, Medina-Lopez R, Lendinez-Cano G, Cayuela A, et al
    Bladder cancer mortality trends in Spain: 1980-2021.
    Actas Urol Esp (Engl Ed). 2023 Jun 22:S2173-5786(23)00070.
    PubMed    
    Abstract available

  22. PYRGIDIS N, Sokolakis I, Haltmair G, Hatzichristodoulou G, et al
    The perioperative and long-term outcomes of patients with variant histology bladder cancer undergoing radical cystectomy: A propensity score-matched analysis with pure urothelial carcinoma.
    Actas Urol Esp (Engl Ed). 2023 Jun 22:S2173-5786(23)00071.
    PubMed    
    Abstract available

  23. ZHAO Y, Lu K, Yin ZX, Peng YH, et al
    Systematic review and meta-analysis of completely retroperitoneoscopic nephroureterectomy versus traditional retroperitoneoscopic nephroureterectomy in upper tract urothelial carcinoma.
    Medicine (Baltimore). 2023;102:e34112.
    PubMed    
    Abstract available

  24. SUN JX, Xia QD, Zhong XY, Liu Z, et al
    The bladder microbiome of NMIBC and MIBC patients revealed by 2bRAD-M.
    Front Cell Infect Microbiol. 2023;13:1182322.
    PubMed    
    Abstract available

  25. SINGH AM, Guevara-Patino JA, Wang X, Li R, et al
    Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
    BioDrugs. 2023;37:505-520.
    PubMed    
    Abstract available

  26. XIONG CC, Zhu SS, Yan DH, Yao YD, et al
    Rapid and precise detection of cancers via label-free SERS and deep learning.
    Anal Bioanal Chem. 2023;415:3449-3462.
    PubMed    
    Abstract available

  27. TAGUCHI S, Kawai T, Buti S, Bersanelli M, et al
    Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.
    Immunotherapy. 2023;15:827-837.
    PubMed    
    Abstract available

  28. SHI R, Le Tan MT, Lim GH, Du J, et al
    Prognostic Value of Tumor Budding in Urothelial Carcinoma: A Meta-Analysis and Systematic Review.
    Lab Invest. 2023;103:100136.
    PubMed    
    Abstract available

  29. WONG MN, Wu DJ, Lee CT, Zynger DL, et al
    Renal Pelvic Urothelial Carcinoma With Invasion Into Renal Medulla Can Be Redefined as pT2 to Improve Correlation With Survival.
    Mod Pathol. 2023;36:100140.
    PubMed    
    Abstract available

  30. KOWALEWSKI KF, Wieland VLS, Kriegmair MC, Uysal D, et al
    Robotic-assisted Versus Laparoscopic Versus Open Radical Cystectomy-A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
    Eur Urol Focus. 2023;9:480-490.
    PubMed    
    Abstract available

  31. WANG LJ, Liu ZX, Hu W, Liu Y, et al
    [Research Progress in Preoperative Evaluation of Lymph Node Metastasis of Bladder Cancer].
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023;45:464-470.
    PubMed    
    Abstract available

  32. ECKE TH, Meisl CJ, Schlomm T Prof, Rabien A, et al
    BTA stat(R), NMP22(R) BladderChek(R), UBC(R) Rapid Test, and CancerCheck(R) UBC(R) rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.
    Urol Oncol. 2023 Jul 3:S1078-1439(23)00225-9. doi: 10.1016/j.urolonc.2023.
    PubMed    
    Abstract available

  33. ADOMI S, Fujita K, Kita H, Kuwahara K, et al
    Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract Urothelial Carcinoma Compared With Metastatic Urinary Bladder Cancer.
    Cancer Diagn Progn. 2023;3:484-490.
    PubMed    
    Abstract available

  34. SUHARA Y, Urabe F, Hashimoto M, Nakazono M, et al
    A case of eosinophilic cystitis coexisting of superficial bladder cancer, mimicking muscle-invasive cancer.
    IJU Case Rep. 2023;6:230-234.
    PubMed    
    Abstract available

  35. MURATA Y, Shinojima T, Nakahira Y, Hamada M, et al
    Recurrent urethral tumor with neuroendocrine differentiation in a female patient after radical cystectomy for bladder cancer.
    IJU Case Rep. 2023;6:199-202.
    PubMed    
    Abstract available

  36. NIE J, Liu T, Mao T, Yang H, et al
    Transcriptome sequencing and single-cell sequencing analysis identify GARS1 as a potential prognostic and immunotherapeutic biomarker for multiple cancers, including bladder cancer.
    Front Immunol. 2023;14:1169588.
    PubMed    
    Abstract available

  37. SHAKHSSALIM N, Talebi A, Pahlevan-Fallahy MT, Sotoodeh K, et al
    Lifestyle and occupational risks assessment of bladder cancer using machine learning-based prediction models.
    Cancer Rep (Hoboken). 2023 Jul 5:e1860. doi: 10.1002/cnr2.1860.
    PubMed    
    Abstract available

  38. ALAMEDDINE R, Mallea P, Shahab F, Zakharia Y, et al
    Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives.
    Curr Treat Options Oncol. 2023 Jul 5. doi: 10.1007/s11864-023-01114.
    PubMed    
    Abstract available

  39. SHOAYDAROV MA, Martov AG, Andronov AS, Dutov SV, et al
    [Experience in the use of confocal laser endomicroscopy for the diagnosis of bladder papillary tumors].
    Urologiia. 2023;:99-106.
    PubMed    
    Abstract available

  40. GUIGNAND A, Bouleftour W, Vassal C, Tinquaut F, et al
    The Impact of an Enrolment in Clinical Trial on Tolerance and Pathological Response for Patients Treated by Neoadjuvant MVAC Against an Invasive Bladder Cancer. A Retrospective Comparative Study.
    Clin Genitourin Cancer. 2023 Jun 15:S1558-7673(23)00145.
    PubMed    
    Abstract available

  41. RAFIEI S, Kheradkhah G, Kotronoulas G, Doustmehraban M, et al
    Quality of life in bladder cancer: systematic review and meta-analysis.
    BMJ Support Palliat Care. 2023 Jul 3:spcare-2023-004185.
    PubMed    
    Abstract available

  42. LI Y, Chen T, Fu B, Luo Y, et al
    Survival nomogram for high-grade bladder cancer patients after surgery based on the SEER database and external validation cohort.
    Front Oncol. 2023;13:1164401.
    PubMed    
    Abstract available

  43. ZHANG M, Zhu J, Zhang P, Li L, et al
    Development and validation of cancer-associated fibroblasts-related gene landscape in prognosis and immune microenvironment of bladder cancer.
    Front Oncol. 2023;13:1174252.
    PubMed    
    Abstract available

  44. ZIANI I, Ibrahimi A, Zaoui Y, El Sayegh H, et al
    Role of preoperative neutrophil to lymphocyte ratio in prediction of recurrence, progression, and BCG failure in non-muscle invasive bladder cancer: a retrospective study.
    Pan Afr Med J. 2023;44:145.
    PubMed    
    Abstract available

  45. AGRAWAL M, Malvi G, Agrawal N, Narayanaswamy S, et al
    Ileal neobladder adenocarcinoma occurring twenty-five years post ileocystoplasty: a case report.
    Pan Afr Med J. 2023;44:149.
    PubMed    
    Abstract available

  46. ZHAN Y, Chen Z, Li Y, He A, et al
    Correction: Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA.
    J Exp Clin Cancer Res. 2023;42:157.
    PubMed    


  47. LI Z, Fu H, Liu J, Song W, et al
    LncRNA PVT1 promotes bladder cancer progression by forming a positive feedback loop with STAT5B.
    Pathol Res Pract. 2023;248:154635.
    PubMed    
    Abstract available

  48. JU M, Wu W, Qu J, Sun Y, et al
    Downregulation of circular RNA hsa_circ_0087856 sensitizes bladder cancer cells to cisplatin through targeting miR-1184/CITED2 signaling.
    Environ Mol Mutagen. 2023 Jul 1. doi: 10.1002/em.22561.
    PubMed    
    Abstract available

  49. YANG L, Wu X, Zhou J, Song P, et al
    Second malignant tumors and non-tumor causes of death for patients with localized and regional kidney cancer after diagnosis.
    Eur J Med Res. 2023;28:206.
    PubMed    
    Abstract available

  50. CANO VELASCO J, Polanco Pujol L, Moreno Cortes JC, Lafuente Puentedura A, et al
    Bladder Epicheck(R) for surveillance in high-risk non-muscle-invasive bladder cancer: Initial experience.
    Actas Urol Esp (Engl Ed). 2023 Jun 28:S2173-5786(23)00075.
    PubMed    


  51. QIU S, Qiu Y, Deng L, Nie L, et al
    Cell softness reveals tumorigenic potential via ITGB8/AKT/glycolysis signaling in a mice model of orthotopic bladder cancer.
    Chin Med J (Engl). 2023 Jun 30. doi: 10.1097/CM9.0000000000002710.
    PubMed    
    Abstract available

  52. FENG J, Wang M, Du GS, Peng K, et al
    Crosstalk between autophagy and bladder transitional cell carcinoma by autophagy-related lncRNAs.
    Medicine (Baltimore). 2023;102:e34130.
    PubMed    
    Abstract available

  53. TERLEVIC R, Ulamec M, Stimac G, Murgic J, et al
    Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16.
    Biomol Biomed. 2023 Jun 21. doi: 10.17305/bb.2023.9242.
    PubMed    
    Abstract available

  54. DIXON S, Hill H, Flight L, Khetrapal P, et al
    Cost-Effectiveness of Robot-Assisted Radical Cystectomy vs Open Radical Cystectomy for Patients With Bladder Cancer.
    JAMA Netw Open. 2023;6:e2317255.
    PubMed    
    Abstract available

  55. TANG Y, Lin L, Xiao Y, Meng L, et al
    Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
    Clin Transl Oncol. 2023 Jun 30. doi: 10.1007/s12094-023-03264.
    PubMed    
    Abstract available

  56. SATCHITHANANTHAM V, Babiker T, Riding G, Banihani M, et al
    A case of mycotic infrarenal abdominal aortic aneurysm after bacillus Calmette-Guerin immunotherapy for bladder cancer and a review of the literature.
    J Vasc Surg Cases Innov Tech. 2023;9:101213.
    PubMed    
    Abstract available

  57. LONGEVITY OMAC
    Retracted: LINC00958 Inhibits Autophagy of Bladder Cancer Cells via Sponge Adsorption of miR-625-5p to Promote Tumor Angiogenesis and Oxidative Stress.
    Oxid Med Cell Longev. 2023;2023:9812826.
    PubMed    
    Abstract available


  58. Y Chromosome Loss Drives Bladder Cancer Aggressiveness and Immune Evasion.
    Cancer Discov. 2023 Jun 30:OF1. doi: 10.1158/2159-8290.CD-RW2023.
    PubMed    
    Abstract available

  59. YANG YJ, Xu XQ, Zhang YC, Hu PC, et al
    Establishment of a prognostic model related to tregs and natural killer cells infiltration in bladder cancer.
    World J Clin Cases. 2023;11:3444-3456.
    PubMed    
    Abstract available

  60. SONG W, Li Z, Yang K, Gao Z, et al
    Antisense lncRNA-RP11-498C9.13 promotes bladder cancer progression by enhancing reactive oxygen species-induced mitophagy.
    J Gene Med. 2023 Jun 29:e3527. doi: 10.1002/jgm.3527.
    PubMed    
    Abstract available

  61. ZHANG M, Qin J, Guo X, Li Z, et al
    Recognition Imaging of Trace E-cadherins on the Bladder Cancer Cells Surface during Epithelial-Mesenchymal Transition by Force-Distance Curve-Based AFM.
    Nano Lett. 2023 Jun 29. doi: 10.1021/acs.nanolett.3c01667.
    PubMed    
    Abstract available

  62. PANER GP, Kamat A, Netto GJ, Samaratunga H, et al
    International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non
    Am J Surg Pathol. 2023 Jun 29. doi: 10.1097/PAS.0000000000002077.
    PubMed    
    Abstract available

  63. KOTERAZAWA S, Somiya S, Ito K, Haitani T, et al
    The useful technique of laparoscopic segmental ureterectomy with ureteral reimplantation for distal upper tract urothelial carcinoma.
    Asian J Endosc Surg. 2023;16:666-672.
    PubMed    
    Abstract available

  64. FRANZ A, Plage H, Fendler A, Schlomm T, et al
    [Precision oncology options in urological cancers].
    Urologie. 2023;62:696-704.
    PubMed    
    Abstract available

  65. GRIMM MO, Foller S, Leeder M, Leucht K, et al
    [Antibody-drug conjugates as new therapeutic agents in uro-oncology].
    Urologie. 2023;62:679-684.
    PubMed    
    Abstract available

  66. YAMAMOTO D, Kotake M, Ishibayashi K, Fujimori D, et al
    Robot-assisted low anterior resection for a rectal cancer patient with ileal conduit: A case report.
    Asian J Endosc Surg. 2023;16:608-612.
    PubMed    
    Abstract available

  67. GALFFY G, Lugowska I, Poddubskaya EV, Cho BC, et al
    A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naive, cisplatin-ineligible urothelial cancer.
    ESMO Open. 2023;8:101173.
    PubMed    
    Abstract available

  68. NAKAMURA K, Ishiyama Y, Nemoto Y, Ishihara H, et al
    Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Int J Clin Oncol. 2023;28:913-921.
    PubMed    
    Abstract available

  69. NAKAGAWA R, Nohara T, Naito R, Kadomoto S, et al
    Intravesical BCG therapy with photodynamic diagnosis-guided transurethral resection of bladder tumors improves recurrence-free survival.
    Photodiagnosis Photodyn Ther. 2023;42:103574.
    PubMed    
    Abstract available

  70. MIYAKE M, Hori S, Fujii T, Nishimura N, et al
    Clinical practice of UroVysion(R) urine test in patients with bladder carcinoma in situ treated with intravesical Bacillus Calmette-Guerin.
    Jpn J Clin Oncol. 2023;53:629-632.
    PubMed    
    Abstract available

  71. ROSE KM, Huelster HL, Meeks JJ, Faltas BM, et al
    Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
    Nat Rev Urol. 2023;20:406-419.
    PubMed    
    Abstract available

  72. CASTELLARNAU S, Gaya JM, Espinosa J, Sierra P, et al
    Clinical impact of the suspension of the ERAS protocol on patients undergoing radical cystectomy during the COVID-19 pandemic.
    Actas Urol Esp (Engl Ed). 2023;47:369-375.
    PubMed    
    Abstract available

  73. PANACH-NAVARRETE J, Devis-Peiro A, Lloret-Dura MA, Sanchez-Gimeno S, et al
    Quality of life in patients with non-muscle invasive bladder tumor undergoing adjuvant intravesical treatment.
    Actas Urol Esp (Engl Ed). 2023;47:360-368.
    PubMed    
    Abstract available

  74. CHUNG CJ, Lee HL, Chang CH, Wu CD, et al
    Determination of potential sources of heavy metals in patients with urothelial carcinoma in central Taiwan: a biomonitoring case-control study.
    Environ Geochem Health. 2023;45:5401-5414.
    PubMed    
    Abstract available

  75. MA J, Yu C, Li X, Zhang Y, et al
    A rare case of perivascular epithelioid-cell tumor of the bladder.
    Asian J Surg. 2023;46:2748-2749.
    PubMed    


  76. CHING D, Chiu SK, Van Vliet C, Jasim A, et al
    Primary ALK-Negative TP63-Rearranged Anaplastic Large Cell Lymphoma in the Bladder: Potential for Misdiagnosis.
    Int J Surg Pathol. 2023;31:612-615.
    PubMed    
    Abstract available

  77. ELLERKAMP V, Schmidt A, Warmann SW, Eckert F, et al
    Detailed functional results after bladder-preserving surgery and high-dose-rate brachytherapy in pediatric bladder/prostate rhabdomyosarcoma.
    J Cancer Res Clin Oncol. 2023;149:3161-3170.
    PubMed    
    Abstract available

  78. MELLGARD G, Patel VG, Zhong X, Joshi H, et al
    Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.
    J Cancer Res Clin Oncol. 2023;149:2833-2841.
    PubMed    
    Abstract available

  79. GILES M, Crabb SJ
    Systemic Treatment-Decision Algorithms in Muscle-Invasive Bladder Cancer: Clinical Complexities and Navigating for Improved Outcomes.
    Res Rep Urol. 2023;15:321-331.
    PubMed    
    Abstract available

  80. ZHU Z, Li X, Liu D, Li Z, et al
    A novel signature of aging-related genes associated with lymphatic metastasis for survival prediction in patients with bladder cancer.
    Front Oncol. 2023;13:1140891.
    PubMed    
    Abstract available

  81. TAN WS, Grajales V, Contieri R, Hensley P, et al
    Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes.
    Eur Urol Open Sci. 2023;53:16-22.
    PubMed    
    Abstract available

  82. YU G, Rice S, Heer R, Lewis R, et al
    Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Tr
    Eur Urol Open Sci. 2023;53:67-77.
    PubMed    
    Abstract available

  83. NAKAMURA R, Hasegawa G, Ikeda Y, Hara N, et al
    Complete remission following pembrolizumab therapy for a patient with nephroureterectomy positive-margin carcinoma in situ and bladder cancer unresponsive to Bacille Calmette-Guerin therapy.
    SAGE Open Med Case Rep. 2023;11:2050313X231185444.
    PubMed    
    Abstract available


  84. Effect of SMYD3 on Biological Behavior and H3K4 Methylation in Bladder Cancer [Retraction].
    Cancer Manag Res. 2023;15:625-626.
    PubMed    
    Abstract available

  85. YOU C, Li Q, Yang Y, Qing L, et al
    ASO Visual Abstract: Extraperitoneal Versus Intraperitoneal Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-analysis.
    Ann Surg Oncol. 2023 Jul 12. doi: 10.1245/s10434-023-13855.
    PubMed    


  86. ZHOU T, Chen H, Wang Y, Wen S, et al
    Key Molecules in Bladder Cancer Affect Patient Prognosis and Immunotherapy Efficacy: Further Exploration for CNTN1 and EMP1.
    JCO Precis Oncol. 2023;7:e2200630.
    PubMed    
    Abstract available

  87. VISSING M, Munch Larsen L, Christensen AJ, Owall L, et al
    Calcium electroporation as an adjunct therapy for pembrolizumab-resistant bladder cancer: a case report.
    Acta Oncol. 2023 Jul 12:1-7. doi: 10.1080/0284186X.2023.2226330.
    PubMed    


  88. SHAKHSSALIM N, Dadpour M, Sharifiaghdas F, Narouie B, et al
    Evaluating the Effectiveness of Intravesical Instillation of BCG by Modified Maintenance Method in Patients With High-Risk Ta and T1 Bladder Cancer: A Randomized Clinical Trial.
    Clin Med Insights Oncol. 2023;17:11795549231184682.
    PubMed    
    Abstract available

  89. XIONG S, Dong W, Deng Z, Jiang M, et al
    Value of the application of computed tomography-based radiomics for preoperative prediction of unfavorable pathology in initial bladder cancer.
    Cancer Med. 2023 Jul 11. doi: 10.1002/cam4.6225.
    PubMed    
    Abstract available

  90. JIANG W, Pan C, Guo W, Xu Z, et al
    Pathologic collision of urinary bladder urothelial carcinoma with small cell carcinoma: a case report.
    Diagn Pathol. 2023;18:80.
    PubMed    
    Abstract available

  91. WANG Y, Zhu H, Xu H, Qiu Y, et al
    Senescence-related gene c-Myc affects bladder cancer cell senescence by interacting with HSP90B1 to regulate cisplatin sensitivity.
    Aging (Albany NY). 2023;15.
    PubMed    
    Abstract available

  92. CHANG TC, Shkolyar E, Del Giudice F, Eminaga O, et al
    Real-time Detection of Bladder Cancer Using Augmented Cystoscopy with Deep Learning: a Pilot Study.
    J Endourol. 2023 Jul 11. doi: 10.1089/end.2023.0056.
    PubMed    
    Abstract available

  93. MIYAJIMA K, Suzuki H, Urabe F, Iwatani K, et al
    Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancer.
    Int J Clin Oncol. 2023 Jul 11. doi: 10.1007/s10147-023-02383.
    PubMed    
    Abstract available

  94. FAROOQI AA, Venera R, Kapanova G, Tanbayeva G, et al
    TRAIL-mediated signaling in bladder cancer: realization of clinical efficacy of TRAIL-based therapeutics in medical oncology.
    Med Oncol. 2023;40:236.
    PubMed    
    Abstract available

  95. PENG K, Ding D, Wang N, Du T, et al
    ITIH5, as a predictor of prognosis and immunotherapy response for P53-like bladder cancer, is related to cell proliferation and invasion.
    Mol Omics. 2023 Jul 11. doi: 10.1039/d2mo00322.
    PubMed    
    Abstract available

  96. SINGH A, Osbourne AS, Koshkin VS
    Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer.
    Curr Treat Options Oncol. 2023 Jul 10. doi: 10.1007/s11864-023-01113.
    PubMed    
    Abstract available

  97. COBELLIS G, Torino G, Lisi G, Ilari M, et al
    Pneumovesicoscopic management of bladder neoplasms in children: three case reports.
    Pediatr Med Chir. 2023;45.
    PubMed    
    Abstract available

  98. GU Y, Zhuo H
    Identification of a cancer-associated fibroblast signature for predicting prognosis and immunotherapeutic responses in bladder urothelial carcinoma.
    Aging Male. 2023;26:2233609.
    PubMed    
    Abstract available

  99. LI Z, Yao Y, Qi T, Wu Z, et al
    ACSM6 overexpression indicates a non-inflammatory tumor microenvironment and predicts treatment response in bladder cancer: results from multiple real-world cohorts.
    Front Pharmacol. 2023;14:1222512.
    PubMed    
    Abstract available

  100. ZENG J, Funk J, Lee BR, Hsu CH, et al
    Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era.
    Transl Androl Urol. 2023;12:960-966.
    PubMed    
    Abstract available

  101. OKOBI TJ, Uhomoibhi TO, Akahara DE, Odoma VA, et al
    Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence.
    Cureus. 2023;15:e40031.
    PubMed    
    Abstract available

  102. ZHONG Q, Jiang K, Zhang F, Tian Y, et al
    Exploring the correlation of glycolysis-related chondroitin polymerizing factor (CHPF) with clinical characteristics, immune infiltration, and cuproptosis in bladder cancer.
    Am J Cancer Res. 2023;13:2213-2233.
    PubMed    
    Abstract available

  103. HUANG CP, Lu HL, Shyr CR
    Anti-tumor activity of intratumoral xenogeneic urothelial cell monotherapy or in combination with chemotherapy in syngeneic murine models of bladder cancer.
    Am J Cancer Res. 2023;13:2285-2306.
    PubMed    
    Abstract available

  104. WU L, Chen W, Cao Y, Chen B, et al
    A novel cuproptosis-related lncRNAs signature predicts prognosis in bladder cancer.
    Aging (Albany NY). 2023;15.
    PubMed    
    Abstract available

  105. JIANG Q, Zhou J, Chen Q, Huang Y, et al
    Construction and experimental validation of a macrophage cell senescence-related gene signature to evaluate the prognosis, immunotherapeutic sensitivity, and chemotherapy response in bladder cancer.
    Funct Integr Genomics. 2023;23:228.
    PubMed    
    Abstract available

  106. ZENNAMI K, Takahara K, Nukaya T, Takenaka M, et al
    The Role of Lymph Node Dissection in Patients With Muscle-Invasive Bladder Cancer Who Underwent Radical Cystectomy Following Neoadjuvant Chemotherapy.
    Clin Genitourin Cancer. 2023 Jun 28:S1558-7673(23)00155.
    PubMed    
    Abstract available

  107. JIANG H, Zhu S, Wu B, Su Y, et al
    CDK2 and CDK4 targeted liensinine inhibits the growth of bladder cancer T24 cells.
    Chem Biol Interact. 2023 Jul 7:110624. doi: 10.1016/j.cbi.2023.110624.
    PubMed    
    Abstract available

  108. XIAO K, Peng S, Lu J, Zhou T, et al
    UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer.
    Cell Death Dis. 2023;14:408.
    PubMed    
    Abstract available

  109. KATES M, Chu X, Hahn N, Pietzak E, et al
    Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guerin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naive High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).
    Eur Urol Focus. 2023 Jul 6:S2405-4569(23)00146-3. doi: 10.1016/j.euf.2023.
    PubMed    
    Abstract available

  110. LIU X, Liu L, Wang X, Jin Y, et al
    Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/Keap1 complex in shikonin-induced ROS dependent cell death of human bladder cancer.
    Phytomedicine. 2023;118:154943.
    PubMed    
    Abstract available

  111. ORJI P, Sun H, Isali I, Bell S, et al
    Female sexual function evaluation and intraoperative vaginal reconstruction in bladder cancer.
    World J Urol. 2023 Jul 7. doi: 10.1007/s00345-023-04502.
    PubMed    
    Abstract available

  112. KATES M
    Doing Less with More: Towards a New Paradigm of Non-muscle-invasive Bladder Cancer Care.
    Eur Urol Focus. 2023 Jul 5:S2405-4569(23)00147-5. doi: 10.1016/j.euf.2023.
    PubMed    


  113. GUPTA S, Norgan AP, Erickson LA
    Schistosomiasis of the Urinary Bladder.
    Mayo Clin Proc. 2023;98:1100-1101.
    PubMed    


  114. LEE J, Kim SH, Jeong SH, Han JH, et al
    Pyuria as an independent predictor of intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial carcinoma.
    Investig Clin Urol. 2023;64:353-362.
    PubMed    
    Abstract available

  115. KIM D, Nam W, Kyung YS, You D, et al
    Effect of decreased renal function on poor oncological outcome after radical cystectomy.
    Investig Clin Urol. 2023;64:346-352.
    PubMed    
    Abstract available

  116. ESTEVES M, Duarte M, Oliveira PA, Gil da Costa RM, et al
    SKELETAL MUSCLE SENSITIVITY TO WASTING INDUCED BY UROTHELIAL CARCINOMA.
    Exp Oncol. 2023;45:107-119.
    PubMed    
    Abstract available

  117. GARMANCHUK LV, Yakovlev PG, Ostrovska GV, Stupak YA, et al
    COMPARISON OF 2D AND 3D PRIMARY CELL CULTURES OBTAINED FROM EXPLANT OF HIGH-GRADE UROTHELIAL BLADDER CANCER.
    Exp Oncol. 2023;45:130-136.
    PubMed    
    Abstract available

  118. TANG Z, Peng J, Wu S, Zhao F, et al
    Combined use of a 980‑nm diode laser and preoperative intravesical instillation of pirarubicin for the prevention of short‑term recurrence of non‑muscle invasive bladder cancer: A pilot study.
    Oncol Lett. 2023;26:322.
    PubMed    
    Abstract available

  119. SU Y, Chen L, Yang J
    Network pharmacology and in vitro experiments reveal that Noscapine induces ROS-mediated apoptosis and cell cycle arrest via PI3K/Akt/FoxO3a signaling pathway in human bladder cancer cells.
    Curr Cancer Drug Targets. 2023 Jul 6. doi: 10.2174/1568009623666230706153936.
    PubMed    
    Abstract available

  120. RODRIGUES L, Watson J, Feng Y, Lewis B, et al
    Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics.
    Sci Rep. 2023;13:10935.
    PubMed    
    Abstract available

  121. YU H, Bai K, Cheng Y, Lv J, et al
    Clinical significance, tumor immune landscape and immunotherapy responses of ADAR in pan-cancer and its association with proliferation and metastasis of bladder cancer.
    Aging (Albany NY). 2023;15.
    PubMed    
    Abstract available

  122. RELPH K, Arif M, Pandha H, Annels N, et al
    Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21.
    Methods Mol Biol. 2023;2684:319-327.
    PubMed    
    Abstract available

  123. GRANDI P, Darilek A, Moscu A, Pradhan A, et al
    Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer.
    Methods Mol Biol. 2023;2684:303-317.
    PubMed    
    Abstract available

  124. NIEGISCH G
    Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma.
    Methods Mol Biol. 2023;2684:293-301.
    PubMed    
    Abstract available

  125. BAHLINGER V, Eckstein M, Hartmann A, Stohr R, et al
    Evaluation of FGFR Alteration Status in Urothelial Tumors.
    Methods Mol Biol. 2023;2684:283-291.
    PubMed    
    Abstract available

  126. MENECEUR S, Grunewald CM, Niegisch G, Hoffmann MJ, et al
    Epigenetic Priming and Development of New Combination Therapy Approaches.
    Methods Mol Biol. 2023;2684:259-281.
    PubMed    
    Abstract available

  127. BAHLINGER V, Hartmann A, Eckstein M
    Assessment of PD-L1 Status in Urothelial Cancer.
    Methods Mol Biol. 2023;2684:249-255.
    PubMed    
    Abstract available

  128. NIKKOLA J, Black P
    Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive Bladder Cancer.
    Methods Mol Biol. 2023;2684:229-247.
    PubMed    
    Abstract available

  129. ZVEREVA M, Hosen MI, Forey N, Sheikh M, et al
    Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-invasive Diagnosis of Urothelial Cancer.
    Methods Mol Biol. 2023;2684:213-228.
    PubMed    
    Abstract available

  130. ECKE TH, Benderska-Soder N, Bismarck E, van Rhijn BWG, et al
    Considering the Effects of Modern Point-of-Care Urine Biomarker Assays in Follow-Up of Patients with High-Risk Non-muscle-Invasive Bladder Cancer.
    Methods Mol Biol. 2023;2684:199-212.
    PubMed    
    Abstract available

  131. NORDENTOFT I, Birkenkamp-Demtroder K, Dyrskjot L
    NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA.
    Methods Mol Biol. 2023;2684:179-197.
    PubMed    
    Abstract available

  132. DONELAN W, Crispen PL, Kusmartsev S
    Tissue Slice Culture and Analysis of Tumor-Associated Hyaluronan in Urothelial Carcinoma.
    Methods Mol Biol. 2023;2684:167-175.
    PubMed    
    Abstract available

  133. MANTWILL K, Nawroth R
    Genome-Wide CRISPR Screening for the Identification of Therapy Resistance-Associated Genes in Urothelial Carcinoma.
    Methods Mol Biol. 2023;2684:155-165.
    PubMed    
    Abstract available

  134. PARK Y, Lelo A, Harris B, Berry DL, et al
    Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry.
    Methods Mol Biol. 2023;2684:145-151.
    PubMed    
    Abstract available

  135. RAMPIAS T, Klinakis A
    Using Sister Chromatid Exchange Assay to Detect Homologous Recombination Deficiency in Epigenetically Deregulated Urothelial Carcinoma Cells.
    Methods Mol Biol. 2023;2684:133-144.
    PubMed    
    Abstract available

  136. SEILLIER L, Peifer M
    Reconstructing Phylogenetic Relationship in Bladder Cancer: A Methodological Overview.
    Methods Mol Biol. 2023;2684:113-132.
    PubMed    
    Abstract available

  137. PETER C, Schulz WA, Whongsiri P
    Characterization of Native COMPASS Complex in Urothelial Carcinoma Cells by Size Exclusion Chromatography.
    Methods Mol Biol. 2023;2684:101-109.
    PubMed    
    Abstract available

  138. MOKOU M, Narayanasamy S, Stroggilos R, Balaur IA, et al
    A Drug Repurposing Pipeline Based on Bladder Cancer Integrated Proteotranscriptomics Signatures.
    Methods Mol Biol. 2023;2684:59-99.
    PubMed    
    Abstract available

  139. OLAH C, Szarvas T
    A Panel-Based Method for the Reproduction of Distinct Molecular Subtype Classifications of Muscle-Invasive Urothelial Bladder Cancer.
    Methods Mol Biol. 2023;2684:27-43.
    PubMed    
    Abstract available

  140. BOSHERZ MS, Samarska IV, Gaisa NT
    Scoring Systems for Immunohistochemistry in Urothelial Carcinoma.
    Methods Mol Biol. 2023;2684:3-25.
    PubMed    
    Abstract available

  141. REIGNIER PL, Gauthier H, Hennequin C, Aussedat Q, et al
    Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer.
    World J Urol. 2023 Jul 6. doi: 10.1007/s00345-023-04506.
    PubMed    
    Abstract available

  142. KAWADA T, Yanagisawa T, Bekku K, Laukhtina E, et al
    Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis.
    Immunotherapy. 2023;15:933-943.
    PubMed    
    Abstract available

  143. FARSHADPOUR F, Taherkhani R, Farzaneh M
    Human papillomaviruses and bladder cancer risk: first report in south of Iran.
    Virusdisease. 2023;34:257-262.
    PubMed    
    Abstract available

  144. BUDENBENDER B, Kother AK, Kriegmair MC, Grune B, et al
    Getting specific: participation preference in urooncological decision-making.
    BMC Med Inform Decis Mak. 2023;23:114.
    PubMed    
    Abstract available

  145. GU YM, Liang XL, Zhang YG, Zhao HY, et al
    [Clinicopathological Features of Primary Small Cell Neuroendocrine Carcinoma of the Bladder].
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023;45:429-435.
    PubMed    
    Abstract available

  146. PARK JY, Baek JW, Yu J, Kim CS, et al
    Vitamin C and catheter-related bladder discomfort after transurethral resection of bladder tumor: A double-blind, randomized, placebo-controlled study.
    J Clin Anesth. 2023;89:111191.
    PubMed    
    Abstract available

  147. ABDELBARY AM, Atwa HA, Elfarargy OM, Qasem ER, et al
    Prognostic Implications of CD24, SOX2, and Nanog Expression in Invasive Urothelial Carcinoma.
    Appl Immunohistochem Mol Morphol. 2023;31:421-428.
    PubMed    
    Abstract available

  148. KANNO T, Kobori G, Ito K, Nakagawa H, et al
    Atypical Oncologic Failure After Laparoscopic Radical Nephroureterectomy in a Japanese Multicenter Study.
    J Endourol. 2023;37:793-800.
    PubMed    
    Abstract available

  149. YU J, Lee J, Kim CS, Park JY, et al
    ASO Author Reflections: Chart-Derived Frailty Index and 1-Year Mortality After Radical Cystectomy.
    Ann Surg Oncol. 2023;30:5304-5305.
    PubMed    


  150. MATTHEW-ONABANJO AN, Nortey G, Matulewicz RS, Basak R, et al
    Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot.
    Curr Probl Cancer. 2023;47:100958.
    PubMed    
    Abstract available

  151. HACKING SM, Pavlick D, Wang Y, Carneiro BA, et al
    Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy.
    Oncologist. 2023;28:e508-e519.
    PubMed    
    Abstract available

  152. SHI Y, Wang S, Liu W, Sherryn S, et al
    Single-Position Complete Retroperitoneoscopic Radical Nephroureterectomy with Bladder Cuff Excision for Upper Urinary Tract Urothelial Carcinoma.
    J Endourol. 2023;37:768-774.
    PubMed    
    Abstract available

  153. ZHAO Q, Wu L, Yang F, Chen D, et al
    A Modified and Practical Surgical Technique for Pure Transperitoneal Laparoscopic Radical Nephroureterectomy in a Single Position and Research Outcomes.
    J Laparoendosc Adv Surg Tech A. 2023;33:691-697.
    PubMed    
    Abstract available

  154. SUN JX, An Y, Xu MY, Liu CQ, et al
    Development of a dynamic risk system for predicting the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer after thulium laser resection of bladder tumor or transurethral resection of bladder tumor followed by intra
    Front Oncol. 2023;13:1133161.
    PubMed    
    Abstract available

  155. CHAI J, Yin S, Feng W, Zhang T, et al
    The Role of Hypoxia-inducible Factor-1 in Bladder Cancer.
    Curr Mol Med. 2023 Jul 20. doi: 10.2174/1566524023666230720163448.
    PubMed    
    Abstract available

  156. ALBARAKATI N, Al-Ghamdi H, Al-Sowayan B, Alshareeda A, et al
    Homologous recombination mRNAs (RAD21, RAD50 and BARD1) have a potentially poor prognostic role in ERBB2-low bladder cancer patients.
    Sci Rep. 2023;13:11738.
    PubMed    
    Abstract available

  157. CHEN G, Fan X, Wang T, Zhang E, et al
    A machine learning model based on MRI for the preoperative prediction of bladder cancer invasion depth.
    Eur Radiol. 2023 Jul 20. doi: 10.1007/s00330-023-09960.
    PubMed    
    Abstract available

  158. ANDRADE DL, Jalalizadeh M, Salustiano ACC, Reis LO, et al
    Bladder cancer immunomodulatory effects of intravesical Nitazoxanide, Rapamycin, Thalidomide and Bacillus Calmette-Guerin (BCG).
    World J Urol. 2023 Jul 20. doi: 10.1007/s00345-023-04526.
    PubMed    
    Abstract available

  159. GOYAL S, Vias P, Periasamy K, Madan R, et al
    Delineating and sparing the ileal conduit in adjuvant radiotherapy for bladder cancer with modulated radiotherapy.
    J Cancer Res Ther. 2023;19:731-737.
    PubMed    
    Abstract available

  160. KUMAR A, Kumar M, Semwal MK, Singh U, et al
    Management of surgically inoperable muscle-invasive bladder cancer in a resource constraint setting at a tertiary care center by bladder preservation protocol: Case series.
    J Cancer Res Ther. 2023;19:725-730.
    PubMed    
    Abstract available

  161. MOHANTY P, Mohapatra AS, Sabat D, Nayak J, et al
    Unusual histomorphological spectrum of urinary bladder cancers and their treatment modalities revisited: Our experience with series of five cases.
    J Cancer Res Ther. 2023;19:617-623.
    PubMed    
    Abstract available

  162. AKBULUT F, Pazir Y, Esmeray A, Erbin A, et al
    The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance.
    Urologia. 2023 Jul 20:3915603231189022. doi: 10.1177/03915603231189022.
    PubMed    
    Abstract available

  163. ECKE TH, Lotan Y, Massfelder T
    Editorial: Identifying novel biomarkers in bladder cancer.
    Front Oncol. 2023;13:1191736.
    PubMed    


  164. RAHMAN KMM, Foster BA, You Y
    Preclinical evaluation of singlet oxygen-cleavable prodrugs in combination with protoporphyrin IX-photodynamic therapy in an orthotopic rat model of non-muscle-invasive bladder cancer(dagger).
    Photochem Photobiol. 2023 Jul 20. doi: 10.1111/php.13838.
    PubMed    
    Abstract available

  165. TAN WS, McElree IM, Davaro F, Steinberg RL, et al
    Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guerin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2023 Jul 18:S2588-9311(23)00143.
    PubMed    
    Abstract available

  166. FARMANI F, Soleimani N, Razeghi M, Zamani A, et al
    Uninvited guest, Balantidium coli in urine in a patient with bladder cancer: A case report and review of the literature.
    Clin Case Rep. 2023;11:e7494.
    PubMed    
    Abstract available

  167. ZHAN Y, Chen Z, He S, Gong Y, et al
    Correction: Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2.
    Mol Cancer. 2023;22:115.
    PubMed    


  168. GUAN H, Wang G, Wang W, Zhou Y, et al
    Postoperative adjuvant radiotherapy for patients with upper tract urothelial carcinoma (UTUC) who underwent kidney-sparing surgery (KSS): a single-center study.
    Radiat Oncol. 2023;18:120.
    PubMed    
    Abstract available

  169. LIU W, Xiong J, Wang H, Li S, et al
    Racial disparities in conditional survival of patients with bladder cancer: a population-based study.
    BMC Urol. 2023;23:122.
    PubMed    
    Abstract available

  170. KOUHEN F, Dahbi Z, Afif M, Chihabeddine M, et al
    Bladder carcinosarcoma treated by cystectomy and adjuvant chemotherapy with good outcomes: a case report.
    J Med Case Rep. 2023;17:320.
    PubMed    
    Abstract available

  171. LAUKHTINA E, Shariat SF
    Smoking, ethnicity and bladder cancer - implications for public health and clinical practice.
    Nat Rev Urol. 2023 Jul 18. doi: 10.1038/s41585-023-00804.
    PubMed    


  172. WANG P, Joiner M, Dzul S, Miller SR, et al
    Adenocarcinoma involving the urinary bladder.
    BMJ Case Rep. 2023;16:e252747.
    PubMed    
    Abstract available

  173. SHEN C, Liu J, Jiao W, Zhang X, et al
    A feed-forward loop based on aerobic glycolysis and TGF-beta between tumor-associated macrophages and bladder cancer cells promoted malignant progression and immune escape.
    J Cancer Res Clin Oncol. 2023 Jul 18. doi: 10.1007/s00432-023-05164.
    PubMed    
    Abstract available

  174. RASTEGAR-POUYANI N, Montazeri V, Marandi N, Aliebrahimi S, et al
    The impact of Cancer-Associated Fibroblasts on drug resistance, stemness, and epithelial-mesenchymal transition in Bladder Cancer: A comparison between recurrent and non-recurrent patient-derived CAFs.
    Cancer Invest. 2023 Jul 18:1-16. doi: 10.1080/07357907.2023.2237576.
    PubMed    
    Abstract available

  175. ABE T, Yamada S, Kikuchi H, Sazawa A, et al
    Impact of postoperative complications on long-term survival in bladder cancer patients.
    Jpn J Clin Oncol. 2023 Jul 17:hyad079. doi: 10.1093.
    PubMed    
    Abstract available

  176. PING Q, Wang C, Cheng X, Zhong Y, et al
    TGF-beta1 dominates stromal fibroblast-mediated EMT via the FAP/VCAN axis in bladder cancer cells.
    J Transl Med. 2023;21:475.
    PubMed    
    Abstract available

  177. ARTYMOWICZ M, Struck-Lewicka W, Wiczling P, Markuszewski M, et al
    Targeted quantitative metabolomics with a linear mixed-effect model for analysis of urinary nucleosides and deoxynucleosides from bladder cancer patients before and after tumor resection.
    Anal Bioanal Chem. 2023 Jul 18. doi: 10.1007/s00216-023-04826.
    PubMed    
    Abstract available

  178. XIA T, Zhou F, Zhang D, Jin X, et al
    Deep-profiling of phospholipidome via rapid orthogonal separations and isomer-resolved mass spectrometry.
    Nat Commun. 2023;14:4263.
    PubMed    
    Abstract available

  179. MURAOKA K, Fukasawa M, Fukushima M, Kumagai M, et al
    [The Effect of Naldemedine Tosylate on the Postoperative Course of Robot-Assisted Radical Cystectomy].
    Hinyokika Kiyo. 2023;69:147-150.
    PubMed    
    Abstract available

  180. HE K, Wang J, Zhou Y, Huang Z, et al
    Network pharmacology analysis of icariside II against bladder cancer.
    Eur J Pharmacol. 2023 Jul 15:175914. doi: 10.1016/j.ejphar.2023.175914.
    PubMed    
    Abstract available

  181. MATAR M, Prince G, Hamati I, Baalbaky M, et al
    Implication of KDM6A in bladder cancer.
    Pharmacogenomics. 2023 Jul 17. doi: 10.2217/pgs-2023-0027.
    PubMed    
    Abstract available

  182. QI G, Liu J, Tao S, Fan W, et al
    A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms.
    PeerJ. 2023;11:e15675.
    PubMed    
    Abstract available

  183. ZHANG Y, Liu M, Wang J, Han K, et al
    Bibliometric analysis of the association between drinking water pollution and bladder cancer.
    Front Oncol. 2023;13:1170700.
    PubMed    
    Abstract available

  184. YI X, Pi J, Liu C, Xiong Y, et al
    The relationship between inflammatory response markers and the prognosis of non-muscle invasive bladder cancer and the development of a nomogram model.
    Front Oncol. 2023;13:1189086.
    PubMed    
    Abstract available

  185. WANG XX, Wu HY, Yang Y, Ma MM, et al
    CCNB1 is involved in bladder cancer pathogenesis and silencing CCNB1 decelerates tumor growth and improves prognosis of bladder cancer.
    Exp Ther Med. 2023;26:382.
    PubMed    
    Abstract available

  186. WANG Y, Kong Q, Li M, Gu J, et al
    Prediction of immune and targeted drug efficacy in pain-related risk subtypes for bladder cancer patients.
    Heliyon. 2023;9:e17690.
    PubMed    
    Abstract available

  187. SU Y, Ai J, Jia M, Yue G, et al
    The Relationship between VEGF and AGT Gene Single Nucleotide Polymorphisms and Susceptibility to Renal and Bladder Cancers.
    Arch Esp Urol. 2023;76:298-308.
    PubMed    
    Abstract available

  188. SHAHAIT M, Abu-Hijlih R, Farkouh A, Obeidat S, et al
    Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: a single institution experience.
    J Egypt Natl Canc Inst. 2023;35:21.
    PubMed    
    Abstract available

  189. TAPPERO S, Chierigo F, Parodi S, Bandini M, et al
    Radical cystectomy in bladder cancer patients previously treated for prostate cancer: Insights from a large European multicentric series.
    Surg Oncol. 2023;50:101973.
    PubMed    
    Abstract available

  190. CHEN H, Yang W, Li Y, Ji Z, et al
    PLAGL2 promotes bladder cancer progression via RACGAP1/RhoA GTPase/YAP1 signaling.
    Cell Death Dis. 2023;14:433.
    PubMed    
    Abstract available

  191. SUBRAMANYA SK, Li R, Wang Y, Miyamoto H, et al
    Deep learning for histopathological segmentation of smooth muscle in the urinary bladder.
    BMC Med Inform Decis Mak. 2023;23:122.
    PubMed    
    Abstract available

  192. GRASSAUER J, Schmidt J, Cowan A, Gilbert SM, et al
    Downstaging and Survival Associated with Neoadjuvant Immunotherapy Before Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2023 Jul 14:S2588-9311(23)00118.
    PubMed    
    Abstract available

  193. WISSING MD, O'Flaherty A, Dragomir A, Tanguay S, et al
    Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Quebec, Canada.
    BMC Urol. 2023;23:119.
    PubMed    
    Abstract available

  194. CHEN H, Xu C, Fang Z, Mao S, et al
    Cell-Free DNA, MicroRNAs, Proteins, and Peptides as Liquid Biopsy Biomarkers in Prostate Cancer and Bladder Cancer.
    Methods Mol Biol. 2023;2695:165-179.
    PubMed    
    Abstract available

  195. CUI Y, Cao M
    Liquid Biopsy in Bladder Cancer.
    Methods Mol Biol. 2023;2695:111-120.
    PubMed    
    Abstract available

  196. YUAN P, Li S, Xiong S, Zheng F, et al
    Development of a butyrate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis and immunotherapy response in bladder cancer.
    J Cancer Res Clin Oncol. 2023 Jul 14. doi: 10.1007/s00432-023-05067.
    PubMed    
    Abstract available

  197. BIERI U, Kranzbuhler B, Wettstein MS, Fankhauser CD, et al
    Limited Value of Bladder Wash Cytology During Follow-Up of Patients With Non-muscle Invasive Bladder Cancer.
    Cureus. 2023;15:e40283.
    PubMed    
    Abstract available

  198. AVETA A, Cilio S, Contieri R, Spena G, et al
    Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review.
    Int J Mol Sci. 2023;24:10846.
    PubMed    
    Abstract available

  199. JAKUS D, Solic I, Juric I, Borovac JA, et al
    The Impact of the Initial Clinical Presentation of Bladder Cancer on Histopathological and Morphological Tumor Characteristics.
    J Clin Med. 2023;12:4259.
    PubMed    
    Abstract available

  200. DANESHDOUST D, Yin M, Luo M, Sundi D, et al
    Conditional Reprogramming Modeling of Bladder Cancer for Clinical Translation.
    Cells. 2023;12:1714.
    PubMed    
    Abstract available

  201. FERRO M, Falagario UG, Barone B, Maggi M, et al
    Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement.
    Diagnostics (Basel). 2023;13:2308.
    PubMed    
    Abstract available

  202. BOCA B, Caraiani C, Telecan T, Pintican R, et al
    MRI-Based Radiomics in Bladder Cancer: A Systematic Review and Radiomics Quality Score Assessment.
    Diagnostics (Basel). 2023;13:2300.
    PubMed    
    Abstract available

  203. BORGHERESI A, Agostini A, Sternardi F, Cesari E, et al
    Vascular Enlargement as a Predictor of Nodal Involvement in Bladder Cancer.
    Diagnostics (Basel). 2023;13:2227.
    PubMed    
    Abstract available

  204. MCELREE IM, Orzel J, Stubbee R, Steinberg RL, et al
    Sequential intravesical gemcitabine and docetaxel for treatment-naive and previously treated intermediate-risk nonmuscle invasive bladder cancer.
    Urol Oncol. 2023 Jul 11:S1078-1439(23)00228.
    PubMed    
    Abstract available

  205. MA J, Roumiguie M, Hayashi T, Kohada Y, et al
    Long-term Recurrence Rates of Low-risk Non-muscle-invasive Bladder Cancer-How Long Is Cystoscopic Surveillance Necessary?
    Eur Urol Focus. 2023 Jul 11:S2405-4569(23)00153.
    PubMed    
    Abstract available

  206. DAHL DM, Karrison TG, Michaelson MD, Pham HT, et al
    Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.
    Eur Urol Oncol. 2023 Jul 11:S2588-9311(23)00115.
    PubMed    
    Abstract available

  207. MIR MA, Pandith AA, Mansoor S, Baba SM, et al
    Differential expression of SLITRK6 gene as a potential therapeutic target for urothelial carcinoma in particular upper tract cancer.
    Gene. 2023;878:147583.
    PubMed    
    Abstract available

  208. ABDEL-HAFIZ HA, Schafer JM, Chen X, Xiao T, et al
    Y chromosome loss in cancer drives growth by evasion of adaptive immunity.
    Nature. 2023;619:624-631.
    PubMed    
    Abstract available

  209. GOBBO A, Fasulo V, Contieri R, Uleri A, et al
    Clinical and pathological predictors of persistent T1 HG at second resection.
    Urologia. 2023;90:482-490.
    PubMed    
    Abstract available

  210. TIAN BW, Han CL, Wang HC, Yan LJ, et al
    Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis.
    Clin Exp Metastasis. 2023;40:255-287.
    PubMed    
    Abstract available

  211. YONESE I, Ito M, Waseda Y, Kobayashi S, et al
    Impact of diagnostic ureteral catheterization on intravesical tumour recurrence following radical nephroureterectomy for upper tract urothelial carcinoma.
    World J Urol. 2023;41:1869-1875.
    PubMed    
    Abstract available

  212. YANAGISAWA T, Kawada T, Quhal F, Bekku K, et al
    Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
    World J Urol. 2023;41:1763-1774.
    PubMed    
    Abstract available

  213. MOAVRO DE, Andrini L, Iribarne A, Colaci P, et al
    HLA-G expression in transitional bladder carcinoma. Relationship with tumor invasion level and patient survival: Experience in a public hospital in Argentina.
    Hum Immunol. 2023;84:423-427.
    PubMed    
    Abstract available

  214. CHEN M, Jiang J, Chen J, Wang M, et al
    The Clinical Safety and Efficacy of Targeted PD-L1 Therapy with Durvalumab in Solid Tumors.
    Curr Drug Targets. 2023;24:584-598.
    PubMed    
    Abstract available

  215. CERRATO C, Pandolfo SD, Autorino R, Panunzio A, et al
    Gender-specific counselling of patients with upper tract urothelial carcinoma and Lynch syndrome.
    World J Urol. 2023;41:1741-1749.
    PubMed    
    Abstract available

  216. CHAN TC, Pan CT, Hsieh HY, Vejvisithsakul PP, et al
    The autocrine glycosylated-GREM1 interacts with TGFB1 to suppress TGFbeta/BMP/SMAD-mediated EMT partially by inhibiting MYL9 transactivation in urinary carcinoma.
    Cell Oncol (Dordr). 2023;46:933-951.
    PubMed    
    Abstract available

  217. DJORDJEVIC D, Dragicevic S, Vukovic M
    Mini-laparotomy radical cystectomy with limited bowel externalization during ileal conduit urinary diversion reduces the rate of postoperative complications: a match-paired, single centered analysis.
    Acta Chir Belg. 2023;123:362-368.
    PubMed    
    Abstract available

  218. REBEZ G, Runti O, Rizzo M, Trombetta C, et al
    Radical cystectomy and orthotopic neobladder in a patient with a preexisting three-components inflatable penile prosthesis.
    Urologia. 2023;90:584-586.
    PubMed    
    Abstract available

  219. SYMVOULIDIS P, Tsioutis C, Zamboglou C, Agouridis AP, et al
    The Effect of Statins on the Incidence and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis.
    Curr Oncol. 2023;30:6648-6665.
    PubMed    
    Abstract available

  220. KODERA A, Mohammed M, Lim P, Abdalla O, et al
    The Management of Bacillus Calmette-Guerin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article.
    Cureus. 2023;15:e40962.
    PubMed    
    Abstract available

  221. BUI TT, Jang E, Shin JH, Kim TH, et al
    Feasibility of Raman spectroscopic identification of gall bladder cancer using extracellular vesicles extracted from bile.
    Analyst. 2023 Jul 28. doi: 10.1039/d3an00806.
    PubMed    
    Abstract available

  222. TABAEI S, Haghshenas MR, Ariafar A, Gilany K, et al
    Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity.
    Clin Proteomics. 2023;20:28.
    PubMed    
    Abstract available

  223. XUE XL, Zhao S, Xu MC, Li Y, et al
    Circular RNA_0000326 accelerates breast cancer development via modulation of the miR-9-3p/YAP1 axis.
    Neoplasma. 2023;70:430-442.
    PubMed    
    Abstract available

  224. CAO T, Zhou X, Wu X, Zou Y, et al
    Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction.
    Front Immunol. 2023;14:1207544.
    PubMed    
    Abstract available

  225. WANG M, Zhang Z, Li Z, Zhu Y, et al
    E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies.
    Front Immunol. 2023;14:1226057.
    PubMed    
    Abstract available

  226. ZHANG J, Duan H, Feng Z, Han X, et al
    Retraction Note: Acetyl-CoA synthetase 3 promotes bladder cancer cell growth under metabolic stress.
    Oncogenesis. 2023;12:39.
    PubMed    


  227. YANAGISAWA T, Kawada T, von Deimling M, Bekku K, et al
    Repeat Transurethral Resection for Non-muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era.
    Eur Urol Focus. 2023 Jul 24:S2405-4569(23)00173.
    PubMed    
    Abstract available

  228. SINGH A, Choudhary A, Pai V, Viswanath K, et al
    Uncovering the Uncommon: Institutional Insights Into the Clinical and Epidemiological Characteristics of Rarer Forms of Bladder Cancer Beyond Transitional Cell Carcinoma.
    Cureus. 2023;15:e40879.
    PubMed    
    Abstract available

  229. HOSHINA H, Taguchi S, Suyama H, Kishitani K, et al
    Surgical resection of retinoblastoma-associated bladder leiomyosarcoma during pregnancy: a case report.
    BMC Urol. 2023;23:125.
    PubMed    
    Abstract available

  230. BARAL BK, Poudel PR, Rajbhandari M, Karki AJ, et al
    Ultrasound versus Nerve Stimulator Guided Obturator Nerve Block in Patients Undergoing Transurethral Resection of Bladder Tumor.
    J Nepal Health Res Counc. 2023;20:998-1002.
    PubMed    
    Abstract available

  231. SASAKI Y, Daizumoto K, Fukuta K, Shiozaki K, et al
    Lymph node dissection during radical cystectomy for bladder cancer: A two-center comparative study of robotic versus open surgery.
    Asian J Endosc Surg. 2023 Jul 25. doi: 10.1111/ases.13234.
    PubMed    
    Abstract available

  232. SHI ZD, Sun Z, Zhu ZB, Liu X, et al
    Integrated single-cell and spatial transcriptomic profiling reveals higher intratumour heterogeneity and epithelial-fibroblast interactions in recurrent bladder cancer.
    Clin Transl Med. 2023;13:e1338.
    PubMed    
    Abstract available

  233. ALAM SM, Larson M, Srinivasan P, Genz N, et al
    Evaluation of sarcopenia in patients receiving intravesical Bacillus Calmette-Guerin for non-muscle invasive bladder cancer.
    Urol Oncol. 2023 Jul 22:S1078-1439(23)00198.
    PubMed    
    Abstract available

  234. TANG NT, Robinson R, Snook RD, Brown M, et al
    Classification of formalin-fixed bladder cancer cells with laser tweezer Raman spectroscopy.
    Analyst. 2023 Jul 24. doi: 10.1039/d3an00119.
    PubMed    
    Abstract available

  235. SONG Y, Xu T
    Letter to the editor for the article "Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer".
    World J Urol. 2023 Jul 24. doi: 10.1007/s00345-023-04541.
    PubMed    


  236. STEWART R, Richards HL, Houghton S, Sweeney P, et al
    'I Had It. I Don't Think I Have It...But I Do Feel It Will Come Back Somewhere': A Qualitative Investigation of the Experience of People With Non-Muscle Invasive Bladder Cancer.
    Qual Health Res. 2023 Jul 24:10497323231170089. doi: 10.1177/10497323231170089.
    PubMed    
    Abstract available

  237. YAMAMOTO K, Yamamoto K, Nakai G, Fujitani T, et al
    Detection of the Vesical Arteries Using Three-dimensional Digital Subtraction Angiography Relevant to Intra-arterial Infusion Chemotherapy for Bladder Cancer Using Double-balloon Catheters.
    Interv Radiol (Higashimatsuyama). 2023;8:64-69.
    PubMed    
    Abstract available

  238. XIAO X, Peng J, Chen Y, Lu X, et al
    Comprehensive Analysis of Differential Gene Expression and Correlated Immune Infiltration in Bladder Cancer.
    Iran J Public Health. 2023;52:1225-1237.
    PubMed    
    Abstract available

  239. ERDIK A, Cimen HI, Atik YT, Gul D, et al
    Sarcopenia is an independent predictor of survival in patients undergoing radical cystectomy for bladder cancer: a single-centre, retrospective study.
    Cent European J Urol. 2023;76:81-89.
    PubMed    
    Abstract available

  240. WASFIE T, Atherton JM, Villegas SJ, Korbitz H, et al
    Small bowel obstruction secondary to metastatic urothelial bladder cancer.
    SAGE Open Med Case Rep. 2023;11:2050313X231176356.
    PubMed    
    Abstract available

  241. LI Y, Zheng H, Luo Y, Lin Y, et al
    An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis.
    Cancer Commun (Lond). 2023 Jul 22. doi: 10.1002/cac2.12470.
    PubMed    
    Abstract available

  242. ELMEKAWY S, Taha DE, Nabeeh HE, Ibrahim A, et al
    Comparison of holmium laser, bipolar and conventional monopolar transurethral resection of bladder tumour in primary non-muscle invasive bladder cancer.
    J Pak Med Assoc. 2023;73.
    PubMed    
    Abstract available

  243. AHMED NOR EM, Saied EM, Alshenawy HA, Shams Eldeen AA, et al
    The Value Of PD-L1 Immunohistochemical Expression In Egyptian Urinary Bladder Carcinoma Patients.
    J Pak Med Assoc. 2023;73.
    PubMed    
    Abstract available

  244. MO R, Dawulieti J, Chi N, Wu Z, et al
    Self-polymerized platinum (II)-Polydopamine nanomedicines for photo-chemotherapy of bladder Cancer favoring antitumor immune responses.
    J Nanobiotechnology. 2023;21:235.
    PubMed    
    Abstract available

  245. BOONCHAI S, Tanthanuch M, Bejrananda T
    Comparison of the Y-pouch orthotopic neobladder and the Studer technique after radical cystectomy: surgical and functional outcomes from a single-center series.
    World J Surg Oncol. 2023;21:218.
    PubMed    
    Abstract available

  246. DE HERTOGH O
    [Bladder preservation treatments for bladder cancer: Trimodality therapy, an overview of clinical practices in 2023].
    Cancer Radiother. 2023 Jul 20:S1278-3218(23)00124.
    PubMed    
    Abstract available

  247. JIANG P, Ning J, Yu W, Rao T, et al
    FLRT2 suppresses bladder cancer progression through inducing ferroptosis.
    J Cell Mol Med. 2023 Jul 21. doi: 10.1111/jcmm.17855.
    PubMed    
    Abstract available

  248. LI L, Zhang Y, Hu W, Zou F, et al
    MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer.
    J Cell Mol Med. 2023 Jul 21. doi: 10.1111/jcmm.17863.
    PubMed    
    Abstract available

  249. ZHU S, Li H, Fan Y, Tang C, et al
    Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
    BMC Urol. 2023;23:124.
    PubMed    
    Abstract available

  250. WANG Z, Muthusamy V, Petrylak DP, Anderson KS, et al
    Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy.
    NPJ Precis Oncol. 2023;7:70.
    PubMed    
    Abstract available

  251. WANG D, Wang C, Zhou FH
    Identification of the diagnostic value of urine SLC1A5 in bladder cancer based on GEO database.
    Asian J Surg. 2023 Jul 19:S1015-9584(23)01045.
    PubMed    


  252. ZHANG B, Yang L, He Y, Han D, et al
    Role and mechanisms of noncoding RNAs in the regulation of metabolic reprogramming in bladder cancer (Review).
    Int J Mol Med. 2023;52:79.
    PubMed    
    Abstract available

  253. GHATALIA P, Kaur J, Sonpavde G
    Muscle invasive bladder cancer: where is the field headed?
    Expert Opin Biol Ther. 2023 Jul 21:1-15. doi: 10.1080/14712598.2023.2238607.
    PubMed    
    Abstract available

  254. LI B, Hu Y, Li QY, Tang YM, et al
    Procoagulant genes may affect angiogenesis, epithelial-mesenchymal transition, survival prognosis and tumor immune microenvironment in patients with urothelial carcinoma.
    Aging (Albany NY). 2023;15:6429-6444.
    PubMed    
    Abstract available

  255. SAINT-JACQUES N, Brown PE, Purcell J, Rainham DG, et al
    The Nova Scotia Community Cancer Matrix: A geospatial tool to support cancer prevention.
    Soc Sci Med. 2023;330:116038.
    PubMed    
    Abstract available

  256. GUERRA NL, Matas-Garcia A, Serra-Garcia L, Morgado-Carrasco D, et al
    Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.
    Autoimmun Rev. 2023;22:103375.
    PubMed    
    Abstract available

  257. SAVIN Z, Kupershmidt A, Phollan D, Lazarovich A, et al
    The role of malnutrition universal screening tool in predicting outcomes after radical cystectomy.
    Surg Oncol. 2023;49:101962.
    PubMed    
    Abstract available

  258. RAMOS KS, Li J, Wijdeveld LFJ, van Schie MS, et al
    Long Noncoding RNA UCA1 Correlates With Electropathology in Patients With Atrial Fibrillation.
    JACC Clin Electrophysiol. 2023;9.
    PubMed    
    Abstract available

  259. CHOU LP, Hsu CW, Yang SF, Lee CT, et al
    Clinicopathologic Analysis of Micropapillary Urothelial Carcinoma of the Upper Urinary Tract: Implications for HER2-Targeted Therapy.
    Clin Genitourin Cancer. 2023;21:508.
    PubMed    
    Abstract available

  260. SEKAR RR, Diamantopoulos LN, Bakaloudi DR, Khaki AR, et al
    Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy.
    Clin Genitourin Cancer. 2023;21:507.
    PubMed    
    Abstract available

  261. BELLMUNT J, Chang J, Pavilack-Kirker M, Cappelleri JC, et al
    Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
    Clin Genitourin Cancer. 2023;21:459-466.
    PubMed    
    Abstract available

  262. SLOTMAN A, Xu M, Lindale K, Hardy C, et al
    Quantitative Nuclear Grading: An Objective, Artificial Intelligence-Facilitated Foundation for Grading Noninvasive Papillary Urothelial Carcinoma.
    Lab Invest. 2023;103:100155.
    PubMed    
    Abstract available

  263. RAY CH, Davaro F, Hamilton ZA, Raza J, et al
    Perioperative outcomes of open versus robot-assisted radical cystectomy in octogenarians: a population based analysis.
    J Robot Surg. 2023;17:1629-1635.
    PubMed    
    Abstract available

  264. CHENG L, Lopez-Beltran A, Wang M, Whaley RD, et al
    Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.
    Mod Pathol. 2023;36:100151.
    PubMed    
    Abstract available

  265. LI KP, Chen SY, Wang CY, Wan S, et al
    Comparison between robot-assisted versus open nephroureterectomy for upper tract urothelial carcinoma: outcomes from a pooled analysis.
    J Robot Surg. 2023;17:1227-1238.
    PubMed    
    Abstract available

  266. GUPTA N, Kucirka L, Semerjian A, Pierorazio PM, et al
    Practice Patterns Regarding Female Reproductive Organ-Sparing and Nerve-Sparing Radical Cystectomy Among Urologic Oncologists in the United States.
    Clin Genitourin Cancer. 2023;21:e236-e241.
    PubMed    
    Abstract available

  267. SUN ZJ, Zhao JW, Zhao M, Chen Y, et al
    CD3 high and FoxP3 - tumor-infiltrating lymphocytes in the invasive margin as a favorable prognostic marker in patients with invasive urothelial carcinoma of the bladder.
    Anticancer Drugs. 2023;34:844-851.
    PubMed    
    Abstract available

  268. TACHIBANA M, Tsubouchi K, Fukuhara Y, Aoyagi C, et al
    Factors Related to Overactive Bladder-like Symptoms in Bladder Cancer.
    Anticancer Res. 2023;43:3607-3613.
    PubMed    
    Abstract available

  269. JAHNSON S, Jancke G, Olsson H, Aljabery F, et al
    Bladder cancer grading using the four-tier combination of the World Health Organization (WHO) 1973 and WHO 2004 classifications.
    BJU Int. 2023 Jul 6. doi: 10.1111/bju.16100.
    PubMed    
    Abstract available

  270. SHALA NK, Stenehjem JS, Babigumira R, Liu FC, et al
    Exposure to benzene and other hydrocarbons and risk of bladder cancer among male offshore petroleum workers.
    Br J Cancer. 2023 Jul 18. doi: 10.1038/s41416-023-02357.
    PubMed    
    Abstract available

  271. DE ANGELIS M, Basile G, Scornajenghi CM, Asero V, et al
    Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer.
    Curr Opin Urol. 2023 Jul 3. doi: 10.1097/MOU.0000000000001113.
    PubMed    
    Abstract available

  272. FENG M, Matoso A, Epstein G, Fong M, et al
    Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer.
    Eur Urol. 2023 Jun 27:S0302-2838(23)02830-0. doi: 10.1016/j.eururo.2023.
    PubMed    
    Abstract available

  273. GROENEVELD CS, Sanchez-Quiles V, Dufour F, Shi M, et al
    Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
    Eur Urol. 2023 Jun 27:S0302-2838(23)02885-3. doi: 10.1016/j.eururo.2023.
    PubMed    
    Abstract available

  274. BORREGALES LD, Venkat S, Posada Calderon L, Lewicki P, et al
    A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Jun 21:S0302-2838(23)02900-7. doi: 10.1016/j.eururo.2023.
    PubMed    


  275. KOTI M, Robert Siemens D
    A Step Closer to Predicting Progression After Bacillus Calmette-Guerin Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Jul 1:S0302-2838(23)02948-2. doi: 10.1016/j.eururo.2023.
    PubMed    
    Abstract available

  276. FLAIG TW, Tangen CM, Daneshmand S, Alva AS, et al
    Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
    Eur Urol. 2023 Jul 4:S0302-2838(23)02945-7. doi: 10.1016/j.eururo.2023.
    PubMed    
    Abstract available

  277. LABAKI C, Saad E, Choueiri TK, Bellmunt J, et al
    Oligometastatic Bladder Cancer: Defining a Novel Entity.
    Eur Urol. 2023 Jul 4:S0302-2838(23)02898-1. doi: 10.1016/j.eururo.2023.
    PubMed    


  278. CIGLIOLA A, Mercinelli C, Patane D, Raggi D, et al
    Re: Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis.
    Eur Urol. 2023 Jul 12:S0302-2838(23)02962-7. doi: 10.1016/j.eururo.2023.
    PubMed    


  279. BASILE G, Audenet F, Seisen T, Pradere B, et al
    The Impact of Lineage-specific Transcriptional Factors in Small-cell Bladder Cancer in the Patient Selection Process in Future Clinical Trials.
    Eur Urol. 2023 Jul 25:S0302-2838(23)02969-X. doi: 10.1016/j.eururo.2023.
    PubMed    


  280. MOEEN AM, Faragallah MA, Zarzour MA, Elbehairy AA, et al
    Ileal conduit versus single stoma uretero-cutanoustomy after radical cystectomy in patients >/= 75 years; which technique is better? a prospective randomized comparative study.
    Int Urol Nephrol. 2023;55:1719-1726.
    PubMed    
    Abstract available

  281. KIM SH, Choi BG, Oh JS, Chun HJ, et al
    Upper tract heparin instillation for maintenance of ureteral stent patency.
    Int Urol Nephrol. 2023;55:1893-1897.
    PubMed    
    Abstract available

  282. OPPOLZER IA, Riester J, Buttner R, Burger M, et al
    Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
    Int Urol Nephrol. 2023;55:1943-1949.
    PubMed    
    Abstract available

  283. WANG Z, Yang Z, Qu C, Li J, et al
    Natural killer cells strengthen antitumor activity of cisplatin by immunomodulation and ameliorate cisplatin-induced side effects.
    Int Urol Nephrol. 2023;55:1957-1970.
    PubMed    
    Abstract available

  284. POWLES T, Park SH, Caserta C, Valderrama BP, et al
    Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After >/=2 Years of Follow-Up.
    J Clin Oncol. 2023;41:3486-3492.
    PubMed    
    Abstract available

  285. STEIN JP, Lieskovsky G, Cote R, Groshen S, et al
    Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients.
    J Clin Oncol. 2023;41:3772-3781.
    PubMed    
    Abstract available


  286. JCO Flashback: Long-Term Outcomes of Radical Cystectomy in Patients With Invasive Bladder Cancer (2001).
    J Clin Oncol. 2023;41:3771.
    PubMed    


  287. BOSL GJ
    Flashback Foreword: Radical Cystectomy in the Treatment of Bladder Cancer.
    J Clin Oncol. 2023;41:3769-3770.
    PubMed    


  288. SWINTON M, Mariam NBG, Tan JL, Murphy K, et al
    Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer.
    J Clin Oncol. 2023 Jul 21:JCO2300725. doi: 10.1200/JCO.23.00725.
    PubMed    
    Abstract available

  289. JI J, Lai CH, Wang Q, Hu H, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic But Not Therapeutic. Letter.
    J Urol. 2023 Jul 6:101097JU0000000000003613. doi: 10.1097/JU.0000000000003613.
    PubMed    


  290. TAN WP
    An Atypical Bladder Mass: Extra Adrenal Paraganglioma.
    Urology. 2023;176:e8-e9.
    PubMed    


  291. ERGUN O, Alperen Ozturk S, Kircicek F, Gurdal O, et al
    Increased Plasma Ignition Distance Practice may Prevent the Obturator Reflex Occurrences and Compare of its Effectiveness Versus Obturator Block: A Prospective, Randomized, Controlled Study.
    Urology. 2023;176:226-231.
    PubMed    
    Abstract available

  292. PASTER IC, Chipollini J
    Reply: Gender, Racial and Ethnic Differences in Pathologic Response Following Neoadjuvant Chemotherapy for Bladder Cancer Patients.
    Urology. 2023 Jul 11:S0090-4295(23)00448-X. doi: 10.1016/j.urology.2023.
    PubMed    


  293. SEKAR RR, Maganty A
    Impact of Race, Ethnicity, and Gender on Response to Neoadjuvant Chemotherapy and Survival in Patients With Muscle-invasive Bladder Cancer.
    Urology. 2023 Jul 11:S0090-4295(23)00447-8. doi: 10.1016/j.urology.2023.
    PubMed    


  294. LIU J, Wu P, Lai S, Wang J, et al
    Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning.
    BMC Cancer. 2023;23:574.
    PubMed    
    Abstract available

  295. KERZELI IK, Kostakis A, Turker P, Malmstrom PU, et al
    Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer.
    BMC Cancer. 2023;23:605.
    PubMed    
    Abstract available

  296. LIANG PI, Lai HY, Chan TC, Li WM, et al
    Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.
    BMC Cancer. 2023;23:599.
    PubMed    
    Abstract available

  297. LI W, Liu Z, Jin K, Shao F, et al
    Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    BMC Cancer. 2023;23:661.
    PubMed    
    Abstract available

  298. YUAN Q, Hu J, Yuan F, An J, et al
    Predictive role of pretreatment skeletal muscle mass index for long-term survival of bladder cancer patients: A meta-analysis.
    PLoS One. 2023;18:e0288077.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;